Department of Dermatology, The Warren Alpert Medical School of Brown University, Providence, RI, USA.
Department of Dermatology, Mayo Clinic, Rochester, MN, USA.
Am J Clin Dermatol. 2022 Mar;23(2):167-176. doi: 10.1007/s40257-021-00667-8. Epub 2022 Jan 6.
Hidradenitis suppurativa (HS) is a severe chronic relapsing inflammatory disorder of the hair follicle unit that can cause painful abscesses, nodules, tunnels, and tracts in intertriginous parts of the body. The disease can often result in disfigurement and adversely impact patient quality of life. The management of HS has expanded significantly over the past decade to include multiple modalities, including topical therapies, systemic therapies (non-biologics and biologics), surgical therapies, lifestyle changes, and management of comorbidities. Management can often be clinically challenging and may involve the combination of medical and surgical approaches for optimal results. The purpose of this review is to present an update on non-biologic and non-interventional modalities published in 2019-2021 in the clinical management of HS. With emerging therapies, ongoing clinical trials, and heightened awareness about HS, there is hope that new treatment options will revolutionize the management of patients suffering from HS.
化脓性汗腺炎（HS）是一种严重的慢性复发性毛囊单位炎症性疾病，可导致身体皱褶部位出现疼痛性脓肿、结节、瘘管和窦道。该疾病常导致毁容，并对患者的生活质量产生不利影响。过去十年中，HS 的治疗方法显著扩展，包括多种方式，包括局部治疗、系统治疗（非生物制剂和生物制剂）、手术治疗、生活方式改变以及合并症的管理。治疗常常具有临床挑战性，可能需要结合医学和手术方法以获得最佳效果。本综述的目的是介绍 2019-2021 年发表的关于 HS 临床管理的非生物制剂和非介入性治疗方法的最新进展。随着新疗法的出现、正在进行的临床试验以及对 HS 的认识不断提高，人们希望新的治疗选择将彻底改变 HS 患者的治疗方法。
